2Hsu SW, Chaloupka JC, Fattal D. Rapidly progressive fatal bihemispheric infarction secondary to Moyamoya syndromein association with Graves thyrotoxieosis[J]. AJNR Am J Neuroradiol, 2006,27(3):643--647.
3Jurgilewicz DH, Rogowski F, Lebkowska U, et al. E-seleetin, L- selectin,ICAM-1 and IL-6 concentrations changes in the serum of patients with hyperthyroidism in the early period of radioiodine 1- 131 therapy[J]. Nuclear Medicine Review 2002,5 ( 1 ) : 39 -- 42.
4Faber J, Wiinberg N, Schifter S, et al. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism[J]. Eur J Endocrinol. , 2001,145(4) : 391 -- 396.
5Verberne HJ, Fliers E, Prummel MF, et al. Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis[J]. Thyroid, 2000,10(7):607-- 610.
6Torre G, Barreca A, Borgonovo G, et al. Goiter recurrence in patients submitted to thyroid-stimulating hormone suppression: possible role of insulin-like growth factors and insulin-like growth factorbinding proteins. Surgery,2000 , 127:99-103.
7Marti U, Ruchti C, Kampf J,et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid, 2001,11:137-145.
8McGregor AM,Beck L,Hall R. Cyclosporin A in management of Graves' disease. J R Soc Med, 1985,78: 511-512.
9Brkljacic B,Sucic M, Bozikov V, et al. Treatment of autonomous and toxic thyroid adenomas by percutaneous ultrasound-guided ethanol injection. Acta Radiol, 2001,42: 477-481.
10Del Prete S, Russo D, Caraglia M, et al. Percutaneous ethanol injection of autonomous thyroid nodules with a volume larger than 40ml: three years of follow-up. Clin Radiol,2001,56: 895-901.
